CA2662517A1 - Treatment of cancer - Google Patents

Treatment of cancer Download PDF

Info

Publication number
CA2662517A1
CA2662517A1 CA002662517A CA2662517A CA2662517A1 CA 2662517 A1 CA2662517 A1 CA 2662517A1 CA 002662517 A CA002662517 A CA 002662517A CA 2662517 A CA2662517 A CA 2662517A CA 2662517 A1 CA2662517 A1 CA 2662517A1
Authority
CA
Canada
Prior art keywords
always
compound
group
iodo
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CA002662517A
Other languages
English (en)
French (fr)
Inventor
Jerome Moore
Bruce A. Keyt
John Burnier
Barry M. Sherman
Max Totrov
Valeria Ossovskaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BiPar Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2662517A1 publication Critical patent/CA2662517A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • C07C239/18—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA002662517A 2006-09-05 2007-09-05 Treatment of cancer Withdrawn CA2662517A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84247406P 2006-09-05 2006-09-05
US60/842,474 2006-09-05
PCT/US2007/077651 WO2008030883A2 (en) 2006-09-05 2007-09-05 Treatment of cancer

Publications (1)

Publication Number Publication Date
CA2662517A1 true CA2662517A1 (en) 2008-03-13

Family

ID=39158003

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002662517A Withdrawn CA2662517A1 (en) 2006-09-05 2007-09-05 Treatment of cancer

Country Status (8)

Country Link
US (2) US8143447B2 (enExample)
EP (1) EP2059498A4 (enExample)
JP (1) JP2010502730A (enExample)
CN (1) CN101522609A (enExample)
AU (1) AU2007292387A1 (enExample)
CA (1) CA2662517A1 (enExample)
IL (1) IL197315A0 (enExample)
WO (1) WO2008030883A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101233121A (zh) * 2005-06-10 2008-07-30 彼帕科学公司 Parp调节剂和癌症的治疗
CN101242822B (zh) 2005-07-18 2011-08-24 彼帕科学公司 治疗卵巢癌的药物
CA2655257A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
AU2007292387A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
JP2010502731A (ja) 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法
WO2008030892A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
EP2059802A4 (en) * 2006-09-05 2010-09-08 Bipar Sciences Inc METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF
EP2121139B1 (en) * 2007-01-16 2012-10-10 BiPar Sciences, Inc. Formulations for cancer treatment
JP2011500684A (ja) * 2007-10-19 2011-01-06 バイパー サイエンシズ，インコーポレイティド ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物
NZ586123A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
KR20100102609A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법
EP2224804A4 (en) * 2007-12-07 2011-06-01 Bipar Sciences Inc TREATMENT OF CANCER WITH COMBINATIONS OF TOPOÎSOMERASE INHIBITORS AND PARP INHIBITORS
AU2009212401A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating PARP-mediated diseases
US10519504B2 (en) 2009-05-11 2019-12-31 Berg Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US20120107300A1 (en) * 2010-11-01 2012-05-03 Jeffrey Nathan Schirripa Cannabinoid Compositions and Methods
SG11201408679XA (en) 2012-06-26 2015-01-29 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2017087576A1 (en) * 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US11096909B2 (en) 2016-04-06 2021-08-24 University Of Oulu Compounds for use in the treatment of cancer
EP3655418A4 (en) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. GLIOBLASTOMA TREATMENT METHODS
EP3687501A4 (en) * 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND THEIR USES

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2669583A (en) * 1954-02-16 X-amroo-zralkoxbbenzamdjes
US2006735A (en) * 1932-11-17 1935-07-02 Gen Aniline Works Inc Nitro-aryl amino-aryl amines
LU38172A1 (enExample) * 1957-11-25
US3161564A (en) 1960-10-03 1964-12-15 Salsbury S Lab Dr Veterinary composition containing halo-nitro-benzamides and methods of using same
US3228833A (en) * 1962-12-17 1966-01-11 Sterling Drug Inc Anticoccidial compositions and methods of using same
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
AR204004A1 (es) 1973-04-02 1975-11-12 Lilly Co Eli Procedimientos para preparar derivados de vinblastina leurosidina y leurocristina
FR2456731A1 (fr) 1979-05-16 1980-12-12 Choay Sa Nouveaux derives substitues d'ary
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5032617A (en) * 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5215738A (en) * 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
DE3750093T2 (de) * 1986-01-17 1995-01-26 Daniel G Miller Test zur Feststellung der Empfänglichkeit für DNS-assoziierte Krankheiten.
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4923885A (en) * 1988-08-19 1990-05-08 Merck & Co., Inc. 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
EP0494231A4 (en) 1989-09-26 1992-09-16 The Regents Of The University Of California 6-amino-1,2-benzopyrones useful for treatment of viral diseases
US5719151A (en) * 1990-05-04 1998-02-17 Shall; Sydney Substituted benzene compounds
US5633282A (en) * 1990-05-25 1997-05-27 British Technology Group Limited Inhibition of viral infection
US5637618A (en) * 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
US5232735A (en) 1990-06-01 1993-08-03 Bioresearch, Inc. Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
US5631038A (en) * 1990-06-01 1997-05-20 Bioresearch, Inc. Specific eatable taste modifiers
HUT70024A (en) * 1990-09-28 1995-09-28 Smithkline Beecham Corp Process for preparing water soluble camptothecin analogs
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en) * 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5200524A (en) * 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
JPH06504791A (ja) 1991-04-10 1994-06-02 オクタマー，インコーポレイティド レトロウィルス複製の阻害のための方法
US5652260A (en) 1991-10-22 1997-07-29 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compound useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5516941A (en) * 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5473074A (en) 1991-10-22 1995-12-05 Octamer, Incorporated Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5482975A (en) * 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5877185A (en) * 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
FR2689009B1 (fr) * 1992-03-25 1995-06-23 Oreal Utilisation en teinture, de metaphenylene-diamines soufrees, composition tinctoriale et procede de teinture, nouvelles metaphenylenediamines soufrees.
KR950703280A (ko) * 1992-09-09 1995-09-20 미리암 디.메코너헤이 제초성 벤젠 화합물(Herbicidal Benzene Compounds)
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5783599A (en) 1993-02-24 1998-07-21 Octamer Inc Methods of treating cancer and viral infections with 5-iodo-6-amino-and 5-iodo-6-nitroso-1 2-benzopyrones
DZ1781A1 (fr) 1993-05-21 2002-02-17 Radopah Ltd Agents d'arylation.
JP3025602B2 (ja) * 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US6008250A (en) 1993-05-26 1999-12-28 Bioresearch, Inc. Specific eatable taste modifiers
US6015792A (en) * 1993-05-26 2000-01-18 Bioresearch, Inc. Specific eatable taste modifiers
JPH06345723A (ja) * 1993-06-10 1994-12-20 Sumitomo Seika Chem Co Ltd メルカプトベンズアミドの製造法
JP3495072B2 (ja) * 1993-12-29 2004-02-09 住友精化株式会社 １，２−ベンズイソチアゾール−３−オン類の製造方法
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
JP3720388B2 (ja) * 1994-06-08 2005-11-24 住友精化株式会社 イソチアゾロン誘導体の製造方法
DE69513847T2 (de) * 1994-10-17 2000-07-27 Novartis Ag, Basel Verfahren zur herstellung von substituierten 3-aminobenzonitrilen
JP3777455B2 (ja) * 1994-11-24 2006-05-24 住友精化株式会社 芳香族またはヘテロ芳香族硫黄化合物の製造方法
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
IL123147A (en) 1995-08-02 2004-02-19 Univ Newcastle Ventures Ltd Benzamide imidazole - 4 carboxamide and their use
GB9615619D0 (en) 1996-03-18 1996-09-04 Radopath Ltd Costimulation of TcR/CD3-induced T-Lymphocytes
US5837729A (en) 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US5981575A (en) 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US20050287120A1 (en) 1997-03-21 2005-12-29 Fisher Paul B Cancer - targeted viral vectors
WO1998042328A1 (en) * 1997-03-26 1998-10-01 Biosource Technologies, Inc. Di-aryl ethers and their derivatives as anti-cancer agents
ATE307797T1 (de) 1997-04-10 2005-11-15 Isotechnika Inc Aktivierte iod-verbindungen zur behandlung von krebs und aids
US5908861A (en) 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6121278A (en) 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6514983B1 (en) * 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6235748B1 (en) * 1997-09-03 2001-05-22 Guilford Pharmaceuticals Inc. Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US5922775A (en) 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
US6380193B1 (en) * 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
JP2002515488A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法
US6395749B1 (en) * 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
CO5070700A1 (es) 1998-06-05 2001-08-28 Basf Ag Genes novedosos de (adp-ribosa) polimerasa
CN1331682A (zh) 1998-11-03 2002-01-16 巴斯福股份公司 取代的2－苯基苯并咪唑类,其制备和用途
IL143303A0 (en) 1998-11-27 2002-04-21 Basf Ag Substituted benzimidazoles and their use as parp inhibitors
JP3552934B2 (ja) 1998-12-24 2004-08-11 セントラル硝子株式会社 安息香酸アミド類の製造方法
US6326517B1 (en) 1998-12-10 2001-12-04 Central Glass Company, Limited Method of producing benzamides
US6201020B1 (en) * 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
US6387902B1 (en) * 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
TR200102005T2 (tr) 1999-01-11 2001-12-21 Agouron Pharmaceuticals,Inc. Poli(adp-ribaz) polimerazların trisiklik inhibitörleri.
KR20010101675A (ko) * 1999-01-26 2001-11-14 우에노 도시오 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제
US6423696B1 (en) 1999-04-16 2002-07-23 The United States Of America, As Represented By The Department Of Health & Human Services Inhibition of arylamine N-acetyl transferase
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
US6653316B1 (en) * 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
GB9915995D0 (en) 1999-07-09 1999-09-08 Ahmed S Non-steroidal sulphamate compounds for use as oestrone sulphatase inhibitors
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
US6562830B1 (en) * 1999-11-09 2003-05-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
US6277990B1 (en) 1999-12-07 2001-08-21 Inotek Corporation Substituted phenanthridinones and methods of use thereof
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
AU2001264595A1 (en) * 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
AU1152702A (en) * 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
DE10064423A1 (de) 2000-12-21 2002-07-04 Symyx Technologies Inc Verfahren zur Herstellung substituierter organischer Verbindungen und Verwendung von Katalysatoren für Substitutionsreaktionen
WO2002055076A1 (en) 2001-01-04 2002-07-18 Daiichi Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical preparation
US20020142334A1 (en) 2001-01-30 2002-10-03 Brown Janice A. Methods of detecting poly(ADP-ribose) polymerase enzymatic activity
US20020164633A1 (en) 2001-04-20 2002-11-07 Inotek Pharmaceuticals Corporation Cell-based assay for detecting activation of poly (ADP-ribose) polymerase
EP1397350B1 (en) 2001-05-08 2007-02-28 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
EP1423120A4 (en) 2001-08-15 2005-12-28 Icos Corp 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
CN100490817C (zh) 2002-03-26 2009-05-27 万有制药株式会社 抗肿瘤吲哚并吡咯并咔唑衍生物和其它抗肿瘤药物联合用药
JPWO2003082808A1 (ja) 2002-04-03 2005-08-04 住友製薬株式会社 ベンズアミド誘導体
US20040034078A1 (en) * 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
BRPI0408996A (pt) 2003-03-31 2006-03-28 Pfizer saia de inibidores tricìclicos de poli(adpp-ribose) polimerases
ES2527871T3 (es) * 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
ES2396334T3 (es) * 2003-05-28 2013-02-20 Eisai Inc. Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
US20050004038A1 (en) * 2003-06-27 2005-01-06 Lyon Robert P. Bivalent inhibitors of Glutathione-S-Transferases
PL1660095T3 (pl) 2003-07-25 2010-07-30 Cancer Research Tech Ltd Tricykliczne inhibitory PARP
US20050026933A1 (en) * 2003-08-01 2005-02-03 Wyeth Holdings Corporation Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
EP1663202A1 (en) * 2003-09-04 2006-06-07 Aventis Pharmaceuticals, Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
MXPA06005686A (es) 2003-11-20 2006-08-17 Janssen Pharmaceutica Nv 2-quinolinonas y 2-quinoxalinonas 7-fenilaquilo sustituidas como inhibidores de la poli(adp-ribosa)polimerasa.
KR101118582B1 (ko) 2003-11-20 2012-02-27 얀센 파마슈티카 엔.브이. 폴리(ａｄｐ-리보스)폴리머라제 저해제로서의 6-알케닐 및6-페닐알킬 치환된 2-퀴놀리논 및 2-퀴녹살리논
DK2305221T3 (en) 2003-12-01 2015-08-24 Kudos Pharm Ltd DNA damage repair inhibitors for the treatment of cancer
CA2546657C (en) 2003-12-05 2013-05-14 Janssen Pharmaceutica N.V. 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
JP4948178B2 (ja) 2003-12-10 2012-06-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤としての置換６−シクロヘキシルアルキル置換２−キノリノンおよび２−キノキサリノン
US7439031B2 (en) * 2003-12-15 2008-10-21 The Trustees Of The University Of Pennsylvania Method of identifying compounds that induce cell death by necrosis
US7680864B2 (en) 2004-03-02 2010-03-16 Intel Corporation Method and apparatus for managing access to stored objects based on retention policy
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
JP2005336083A (ja) 2004-05-26 2005-12-08 Sumitomo Chemical Co Ltd 芳香族アミノ化合物の製造方法
CN1980674B (zh) 2004-06-30 2011-05-25 詹森药业有限公司 作为parp抑制剂的2,3-二氮杂萘衍生物
ES2415771T3 (es) 2004-06-30 2013-07-26 Janssen Pharmaceutica N.V. Derivados de quinazolina como inhibidores de PARP
EA012837B1 (ru) 2004-06-30 2009-12-30 Янссен Фармацевтика Н.В. Производные хиназолинона в качестве ингибиторов parp
US20060035890A1 (en) 2004-08-10 2006-02-16 Amit Banerjee Compounds and methods for the treatment of ubiquitin conjugating disorders
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
MX2007002461A (es) * 2004-09-22 2008-03-13 Pfizer Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-{4-[metilamino)metil]fenil}-1, 3, 4, 5-tetrahidro-6h-azepino [5, 4, 3-cd]indol-6-ona.
EP1793830A2 (en) 2004-09-22 2007-06-13 Pfizer, Inc. Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
DE102004050196A1 (de) 2004-10-15 2006-04-20 Sanofi-Aventis Deutschland Gmbh Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
ATE479687T1 (de) * 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
EP1813609B1 (en) 2004-10-29 2013-06-19 Msd K.K. Novel aminopyridine derivatives having selective aurora-a inhibitory effect
CN1768732A (zh) 2004-11-02 2006-05-10 上海富海科申药业有限公司 芳香硝基化合物在制备治疗肿瘤药物中的应用
CN1768733A (zh) 2004-11-02 2006-05-10 上海富海科申药业有限公司 芳香硝基化合物在制备治疗艾滋病药物中的应用
DE102005023834A1 (de) 2004-11-20 2006-05-24 Bayer Healthcare Ag Substituierte[(Phenylethanoyl)amino]benzamide
GB0428111D0 (en) 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
WO2006078503A2 (en) 2005-01-07 2006-07-27 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
WO2006110683A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
CN101233121A (zh) * 2005-06-10 2008-07-30 彼帕科学公司 Parp调节剂和癌症的治疗
CN101242822B (zh) * 2005-07-18 2011-08-24 彼帕科学公司 治疗卵巢癌的药物
CN101370497B (zh) 2006-01-17 2010-11-17 雅培制药有限公司 包含parp抑制剂和细胞毒性剂的联合产品及用途
US20080293795A1 (en) 2006-01-17 2008-11-27 Abbott Laboratories Combination therapy with parp inhibitors
WO2007107305A2 (en) 2006-03-22 2007-09-27 Medigene Ag Treatment of triple receptor negative breast cancer
US20080262062A1 (en) 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2655257A1 (en) 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
DE102006037399A1 (de) * 2006-08-10 2008-02-14 Archimica Gmbh Verfahren zur Herstellung von Arylaminen
AU2007292387A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
WO2008030892A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
JP2010502731A (ja) * 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法
EP2059802A4 (en) * 2006-09-05 2010-09-08 Bipar Sciences Inc METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF
CN101190211B (zh) 2006-11-23 2011-08-10 上海富海科申药业有限公司 芳香硝基化合物在制备治疗病毒性肝炎药物中的应用
EP3536690A1 (en) 2007-01-10 2019-09-11 MSD Italia S.r.l. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
EP2121139B1 (en) 2007-01-16 2012-10-10 BiPar Sciences, Inc. Formulations for cancer treatment
ATE542799T1 (de) 2007-03-08 2012-02-15 Janssen Pharmaceutica Nv Chinolinonderivate als parp und tank-inhibitoren
JP2011500684A (ja) * 2007-10-19 2011-01-06 バイパー サイエンシズ，インコーポレイティド ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物
KR20100102609A (ko) 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법
NZ586123A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
EP2224804A4 (en) 2007-12-07 2011-06-01 Bipar Sciences Inc TREATMENT OF CANCER WITH COMBINATIONS OF TOPOÎSOMERASE INHIBITORS AND PARP INHIBITORS
AU2009212401A1 (en) 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating PARP-mediated diseases
EP2393364A4 (en) 2009-02-04 2013-03-13 Bipar Sciences Inc TREATMENT OF LUNG CANCER WITH A PARP INHIBITOR IN COMBINATION WITH A GROWTH FACTOR INHIBITOR

Also Published As

Publication number Publication date
US20120238601A1 (en) 2012-09-20
WO2008030883A3 (en) 2008-11-06
AU2007292387A1 (en) 2008-03-13
EP2059498A2 (en) 2009-05-20
US8143447B2 (en) 2012-03-27
IL197315A0 (en) 2009-12-24
US20080103104A1 (en) 2008-05-01
CN101522609A (zh) 2009-09-02
JP2010502730A (ja) 2010-01-28
WO2008030883A2 (en) 2008-03-13
EP2059498A4 (en) 2011-01-12

Similar Documents

Publication Publication Date Title
CA2662517A1 (en) Treatment of cancer
TW200745058A (en) MMP-13 selective inhibitors
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
CO6220840A2 (es) Formulaciones para el tratamiento de cancer
CO6190627A2 (es) Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico por imagenes
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
WO2007016392A3 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
CY1110504T1 (el) Αναστολεις κινασης πρωτεϊνης
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
MX2009003927A (es) Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
CN112955454A (zh) 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
MX2020008570A (es) Inhibidores de arginasa y sus metodos de uso.
AR065464A1 (es) Derivados de nicotinamida. composiciones farmaceuticas
ECSP109900A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
IL189003A0 (en) Methods for treating substance-related disorders
DK2061452T3 (da) Anvendelse af koffeinsyre og derivater deraf mod cancer
TW200612920A (en) Novel imidazolidine derivatives
NO20062617L (no) Anvendelse av glukosidase inhibitorer for terapi av mucovisidose
HRP20080598T3 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
WO2008153042A1 (ja) 抗腫瘍剤
ATE464296T1 (de) Selektive nichtsteroidale glucocorticoid-rezeptor-modulatoren
CA2423007A1 (en) Spiro derivatives and adhesion molecule inhibitors containing the same as effective ingredients
TW200621694A (en) Substituted n-sulfonylaminobenzyl-2-phenoxyacetamide compounds

Legal Events

Date Code Title Description
EEER Examination request
AZWI Withdrawn application

Effective date: 20131219